Content about Collaborative Care

January 4, 2013

Sam's Club is offering free health screenings as part of a New Year's promotion, the club retailer said Friday.

BENTONVILLE, Ark. — Sam's Club is offering free health screenings as part of a New Year's promotion, the club retailer said Friday.

The chain will offer free glucose, cholesterol, blood pressure, body mass index and vision screenings at all of its stores that have pharmacies on Jan. 12, from 11 a.m. to 3 p.m.

January 3, 2013

Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

Dr. Reddy's announced the launch of finasteride tablets in the 1-mg strength, a generic version of Merck's Propecia. As the first company to successfully file for approval of a generic version of the drug, Dr. Reddy's is entitled to 180 days of market exclusivity in which to compete directly with the branded version.

Propecia had sales of about $136 million during the 12-month period that ended in October 2012, according to IMS Health.

January 3, 2013

An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said.

WESTON, Mass. — An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said Thursday.

Biogen announced results of its phase-3 trial of dexpramipexole in patients with the disease, known technically as amyotrophic lateral sclerosis, or ALS. The drug failed to improve functioning and survival in patients and failed to show efficacy in key secondary endpoints as well, the company said.

January 3, 2013

The Food and Drug Administration has approved a generic drug for heavy menstrual bleeding made by Watson Pharmaceuticals, the drug maker said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug for heavy menstrual bleeding made by Watson Pharmaceuticals, the drug maker said Thursday.

Watson announced the approval of tranexamic acid tablets through a subsidiary and plans to ship it immediately. The drug is a generic version of Ferring Pharmaceuticals' Lysteda.

Ferring has filed suit against Watson, alleging that the generic drug infringes two of its patents. Lysteda had sales of about $25 million during the 12-month period that ended in November, according to IMS Health.

January 3, 2013

Pfizer's generics division has launched an authorized generic drug for treating epilepsy.

PEAPACK, N.J. — Pfizer's generics division has launched an authorized generic drug for treating epilepsy.

Greenstone announced the introduction of phenytoin tablets in the 50-mg strength, an authorized generic version of Pfizer's Dilantin Infatabs.

Authorized generics are generic drugs marketed under their generic names at a reduced price, often through third-party companies under contract with the original drug's manufacturer.

January 3, 2013

People making New Year's resolutions, mostly centered around health, this year say they behave more responsibly than they did five years ago compared with those not making them, according to a new survey.

BOSTON — People making New Year's resolutions, mostly centered around health, this year say they behave more responsibly than they did five years ago compared with those not making them, according to a new survey.

The online survey, by Liberty Mutual Insurance, included more than 1,700 adults, gauging how Americans define personal responsibility and how their perception of it varies with age, marital status, gender and whether they have children.

January 3, 2013

Reaching out to discharged hospital patients by telephone could help reduce the chances they'll be readmitted in the future, according to a new study by a healthcare service company.

BLOOMFIELD, Conn. — Reaching out to discharged hospital patients by telephone could help reduce the chances they'll be readmitted in the future, according to a new study by a healthcare service company.

January 3, 2013

Par Pharmaceutical Cos. has started shipping two formulations of a generic drug for treating migraines, the company said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has started shipping two formulations of a generic drug for treating migraines, the company said.

Par announced the shipment of rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets in the 5-mg and 10-mg strengths. The drug is used to treat acute migraine with or without aura in patients ages 6 years and older.

The drug has sales of about $653 million per year, according to IMS Health.

January 3, 2013

A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.

WASHINGTON — A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.

Zuckerman Spaeder LLP said the U.S. District Court for the District of Columbia upheld a Food and Drug Administration decision protecting Ranbaxy's market exclusivity for a generic version of Novartis' drug Diovan (valsartan).

January 3, 2013

An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

NORTH WALES, Pa. — An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

The company, which is the branded respiratory division of Israeli drug maker Teva Pharmaceutical Industries, announced the available of ProAir HFA (i.e., albuterol sulfate), for patients aged 4 and older to prevent and treat bronchospasm with reversible obstructive airway disease and prevent exercise-induced bronchospasm. The inhaler received Food and Drug Administration approval in March 2012.

January 2, 2013

The Food and Drug Administration last week approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured by Bristol-Myers Squibb, and marketed by BMS and Pfizer.

PRINCETON, N.J. — The Food and Drug Administration last week approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured by Bristol-Myers Squibb, and marketed by BMS and Pfizer.

January 2, 2013

The U.S. Food and Drug Administration on Monday approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.

SPRING SPRING, Md. — The U.S. Food and Drug Administration on Monday approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection. Diarrhea is experienced by many HIV/AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies.

December 28, 2012

Mylan on Friday announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its phenytoin chewable tablets USP in the 50 mg strength.

 PITTSBURGH — Mylan on Friday announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its phenytoin chewable tablets USP in the 50 mg strength.

The product is a generic version of Pfizer's Dilantin Chewable Tablets, which are indicated for the control of generalized tonic-clonic (i.e., grand mal) and complex partial (i.e., psychomotor, temporal lobe) seizures, and prevention and treatment of seizures occurring during or following neurosurgery.

December 28, 2012

Watson Pharmaceuticals on Friday confirmed that Actavis, which was acquired by Watson in October, has filed an abbreviated new drug applications with the Food and Drug Administration seeking approval to market bortezomib, a generic version of Millennium Pharmaceuticals' Velcade.

PARSIPPANY, N.J. — Watson Pharmaceuticals on Friday confirmed that Actavis, which was acquired by Watson in October, has filed an abbreviated new drug applications with the U.S. Food and Drug Administration seeking approval to market bortezomib, a generic version of Millennium Pharmaceuticals' Velcade.

Bortezomib is a proteasome inhibitor for intravenous or subcutaneous administration, approved for treatment of patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior therapy.

December 27, 2012

The Food and Drug Administration on Monday approved Aegerion Pharmaceuticals' cholesterol drug, Juxtapid.

CAMBRIDGE, Mass. — The Food and Drug Administration on Monday approved Aegerion Pharmaceuticals' cholesterol drug, Juxtapid.

The drug — an alternative treatment for patients who have a genetic predisposition to high cholesterol — will carry a boxed warning, the strongest level of FDA warning. Juxtapid will be available only through a restricted program due to risk of liver damage.

December 27, 2012

A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to research led by St. Jude Children's Hospital.

MEMPHIS  — A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to research led by St. Jude Children's Hospital.

The study found the estimated two-year cancer-free survival for patients enrolled in the study fell from 88% to 75% after the drug cyclophosphamide was substituted for mechlorethamine for treatment of patients with intermeidiate- or high-risk Hodgkin lymphoma. The study was launched before the drug shortages began.

December 21, 2012

The Food and Drug Administration has approved a new drug for reducing the severity of chickenpox symptoms, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for reducing the severity of chickenpox symptoms, the agency said Friday.

The FDA announced the approval of Cangene Corp.'s Varizig (varicella zoster immune globulin [human]) for varicella zoster, the virus that causes chickenpox. The FDA said Varizig was the only FDA-approved immune globulin for the virus after exposure.

December 21, 2012

The Food and Drug Administration has approved a drug to treat a condition that affects people who have had their intestines partially or completely removed, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug to treat a condition that affects people who have had their intestines partially or completely removed, the agency said Friday.

The FDA announced the approval of NPS Pharmaceuticals' Gattex (teduglutide) for daily injection in adults with short bowel syndrome who need additional nutrition from intravenous feeding. SBS results from partial or complete surgical removal of the small or large intestine, which can lead to poor absorption of fluids and nutrients from food.

December 21, 2012

The Food and Drug Administration has approved a common flu drug for use in children as young as 2 weeks old, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a common flu drug for use in children as young as 2 weeks old, the agency said Friday.

The FDA announced the new approval for Genentech's Tamiflu (oseltamivir). The agency said that while patients ages 1 year and older can receive the same dosage, those younger than 1 year must be dosed based on their exact weight.

December 21, 2012

A federal court decision means that a nontamper-resistant formulation of a painkiller made by Endo Health Solutions can enter the market early next month, the drug maker said.

CHADDS FORD, Pa. — A federal court decision means that a nontamper-resistant formulation of a painkiller made by Endo Health Solutions can enter the market early next month, the drug maker said.

The U.S. District Court for the District of Columbia dismissed a case filed by Endo subsidiary Endo Pharmaceuticals against the Food and Drug Administration, in which the company had argued that the FDA failed meet a legal obligation to determine whether the original formulation of Opana ER (oxymorphone) extended-release tablets was withdrawn from the market for safety reasons.

December 21, 2012

A new product from the PediaCare line is designed to keep children hydrated when they have a cold or flu.

TARRYTOWN, N.Y. — A new product from the PediaCare line is designed to keep children hydrated when they have a cold or flu.

Prestige Brands Holdings announced the launch of PediaCare Cold & Flu Hydration, designed to ensure children get needed fluids and electrolytes. The product replenishes nutrients lost from illness and provides immune-boosting antioxidants, with less sugar than sports drinks, soda and juices.

December 21, 2012

Teva Pharmaceutical Industries is buying $1 billion worth of its debt, the Israeli drug maker said.

JERUSALEM — Teva Pharmaceutical Industries is buying $1 billion worth of its debt, the Israeli drug maker said.

Teva said its finance division, Teva Pharmaceutical Finance IV, had called for redemption of its $1 billion outstanding principal amount of 1.700% senior notes due 2014, funded with proceeds from the company's offering of $2 billion principal amount of senior notes, priced on Dec. 13, 2012, and closed Tuesday.

The redemption date will be Jan. 7, 2013.

December 21, 2012

Watson Pharmaceuticals will present at two conferences sponsored by financial banks, the company said.

PARSIPPANY, N.J. — Watson Pharmaceuticals will present at two conferences sponsored by financial banks, the company said.

Watson said that president and CEO Paul Bisaro would provide an overview and update of the company's business at the 2013 Goldman Sachs "Healthcare CEOs Unscripted: A View from the Top" conference, scheduled for Jan. 3, 2013, at the Goldman Sachs Conference Center in New York.

Six days later, on Jan. 9, Bisaro will present at the annual J.P. Morgan Healthcare Conference, at the Westin St. Francis Hotel in San Francisco.

December 20, 2012

An advocacy group said proposed Food and Drug Administration rules for compounding pharmacies would put the public's health and safety at risk.

WASHINGTON — An advocacy group said proposed Food and Drug Administration rules for compounding pharmacies would put the public's health and safety at risk.

In a letter sent to Department of Health and Human Services secretary Kathleen Sebelius, Public Citizen criticized Food and Drug Administration commissioner Margaret Hamburg for "both undermining her agency's authority in congressional testimony last month and offering a plan that would effectively weaken the agency's oversight of drug manufacturing."

December 20, 2012

Generic drug maker Mylan has settled with Orion over a drug used to treat Parkinson's disease, Mylan said Thursday

PITTSBURGH — Generic drug maker Mylan has settled with Orion over a drug used to treat Parkinson's disease, Mylan said Thursday.

The company said it reached a settlement with Orion to resolve patent litigation concerning a generic version of Orion's drug Comtan (entacapone) tablets in the 200-mg strength. The drug is used with levodopa-carbidopa therapy to treat Parkinson's patients who experience signs and symptoms of end-of-dose "wearing off."